Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer
Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer
复制标题
结合珠蛋白 α 亚基和肝细胞生长因子可作为小细胞肺癌的血清肿瘤生物标志物
DOI：
--
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
R. Salgia
中科院分区：
文献类型：
--
作者：
A. Bharti;P. Ma;G. Maulik;Rajeev Singh;Eshan Khan;A. Skarin;R. Salgia
背景：小细胞肺癌（SCLC）经常表现为转移性疾病。在早期阶段检测血清肿瘤生物标志物将有助于提高总生存率。材料与方法：使用来自SCLC患者（6例局限性疾病、7例广泛性疾病、4例复发性疾病、4例治疗后无疾病证据）和5例正常对照的血清样品利用蛋白质组学鉴定肿瘤生物标志物。还使用标准ELISA研究了血清肝细胞生长因子。结果如下：利用基于MALDI-TOF-MS的蛋白质鉴定技术，将SCLC特异性过表达的蛋白质鉴定为触珠蛋白·-亚基，其血清水平与疾病阶段相关。与正常对照组相比，SCLC血清中的·-触珠蛋白的平均水平升高。血清HGF也作为潜在的肿瘤生物标志物进行了研究，发现与疾病状态相关。血清·-触珠蛋白相对水平（高于1.9U）或HGF水平（高于500 pg/ml）与生存率下降的趋势相关。结论：血清·-结合珠蛋白和HGF水平可作为小细胞肺癌的血清肿瘤标志物。现在确定这些血清生物标志物是否响应于该疾病的治疗而改变也是有用的。在美国，预计2003年肺癌新发病例将超过171 900例。预计今年将有157，200人死于肺癌（1）。肺癌的症状有哪些？
Background: Small cell lung cancer (SCLC) frequently presents as metastatic disease. It would be useful to detect serum tumor biomarkers at an earlier stage in order to improve the overall survival. Materials and Methods: Serum samples from SCLC patients (6 limited disease , 7 extensive disease, 4 relapsed disease, 4 no evidence of disease post- treatment) and 5 normal controls were used to identify tumor biomarkers utilizing proteomics. Serum hepatocyte growth factor was also studied using standard ELISA. Results: Utilizing MALDI-TOF-Mass Spectrometry (MS) based protein identification techniques, a SCLC specific overexpressed protein was identified to be haptoglobin ·-subunit, with its serum level correlating with the disease stage. The mean level of ·-haptoglobin was increased in SCLC serum as compared to the normal controls. Serum HGF was also studied as potential tumor biomarker and was found to correlate with the disease status. Either serum ·-haptoglobin relative level (above 1.9 U), or HGF level (above 500 pg/ml) was associated with a trend towards worse survival. Conclusion: Our current findings suggest that serum levels of ·-haptoglobin and HGF may serve as useful serum tumor biomarkers in SCLC. It would now also be useful to determine if these serum biomarkers are altered in response to therapy for this disease. In the United States, there will be greater than 171,900 projected new cases of lung cancer in 2003. It is estimated that there will be 157,200 deaths related to lung cancer for this year (1). The most aggressive form of lung cancer is
影响因子：
11.2
作者：
J. Siegfried;L. Weissfeld;P. Singh-Kaw;R. Weyant;J. Testa;R. Landreneau;R. Landreneau
通讯作者：
J. Siegfried;L. Weissfeld;P. Singh-Kaw;R. Weyant;J. Testa;R. Landreneau;R. Landreneau
影响因子：
11.2
作者：
J. Yamashita;M. Ogawa;S. Yamashita;K. Nomura;M. Kuramoto;T. Saishoji;Sadahito Shin
通讯作者：
J. Yamashita;M. Ogawa;S. Yamashita;K. Nomura;M. Kuramoto;T. Saishoji;Sadahito Shin